1.Greenblatt, DJ, Shader, RI, Abernathy, DR. Current status of benzodiazepines (first of 2 parts), New Engl J Med 1983; 6: 354–358.
2.Herman, J. Interview in Currents in Affective Illness 1988; 7(2): 5–10.
3.Sheehan, DV, Coleman, JH, Greenblatt, DJ, et al.Some biological correlates of panic attacks with agoraphobia and their response to a new treatment. J Clin Psychopharmacology 1984; 4(2): 66–75.
4.Pyke, RE, Cohn, JB, Feighner, JD, Smith, WT. Open label studies of adinazolam in severe depression. Psychopharmacol Bull 1986; 19: 96–98.
5.Feighner, JP. Controlled studies of Deracyn (adinzaolam mesylate) for major depressive episode. Abstract presented at NCDEU Annual Meeting, Key Biscayne, Florida, 1985.
6.Lahti, RA, Sethy, VH, Barsuhn, C, Hester, JB. Pharmacological profile of the antidepressant adinazolam, a triazolobenzodiazepine. Neuropharmacology 1983; 22: 1277–82.
7.Amsterdam, J, Kaplan, M, Potter, L, Bloom, L, Rickels, K. Adinazolam, a new triazolobenzodiazepine and imipramine in the treatment of major depressive disorder. Springer Verlag, 1986.
8.Dunner, D, Myers, J, Khan, A, Avery, D, Pyke, R. Adinazolam, a new antidepressant: findings of a placebo-controlled double-blind study in outpatients with major depression. J. Clin Psychopharmacol 1987; 7: 170–172.
9.Pyke, RE, Greenberg, HS. Double blind comparison of alprazolam and adinazolam for panic and phobic disorders. J Clin Psychopharmacol 1989; 9(1): 15–21.
10.Fleishaker, JC, Phillips, JP, Lau, HSH. Effect of food on the bioavailability of adinazolam from a sustained release formulation: effect of meal timing and lack of dose dumping. Biopharm Drug Disposit. 1990 (in press).
11.American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 3rd edition revised (DSM-1II-R). Washington, D.C. 1987.
12.Spitzer, RL, Williams, JBW. Structured clinical interview for DSM-III-R. Biometrics Research Dept., New York State Psychiatric Institute, New York, 1987. Upjohn Version (SCID-UP-R).
13.Sheehan, DV. The Anxiety Disease. New York, Bantam Books (revised paperback edition), 1986.
14.Hamilton, M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50.
15.Hamilton, M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychology 1967; 6: 278–296.
16.Derogatis, LR, Lipman, RS, Rickles, K, Uhlenhuth, EH, Covi, L. The Hopkins Symptom Checklist (HSCL): A self report symptom inventory. Behav Sci 1974; 19 (1): 1–15.
17.Beck, AT, Ward, CH, Mendelson, M, Mock, JE, Erbaugh, JK. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–571.
18.Winer, BJ. Statistical principles in experimental design. New York: McGraw Hill, 1971.
19.Pecknold, JC, Swinson, RP, Kuch, K, Lewis, CP. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial, III Discontinuation effects. Arch Gen Psychiatry 1988; 45: 429–436.